Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. - Wikidata - awgldk - TriplyDB

Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen.

Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen.

http://www.wikidata.org/entity/Q36954859

about

Genomic screening with RNAi: results and challenges Hypoxia-inducible factors and the response to hypoxic stress State of the science: an update on renal cell carcinoma Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy Targeting melanoma by small molecules: challenges ahead Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth.Use of RNAi screens to uncover resistance mechanisms in cancer cells and identify synthetic lethal interactions.RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.Pooled RNAi Screens - Technical and Biological Aspects.Computational repositioning and preclinical validation of pentamidine for renal cell cancer.A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly.Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3 A decade of systems biology VHL, the story of a tumour suppressor gene.Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm Miniature short hairpin RNA screens to characterize antiproliferative drugs High throughput synthetic lethality screen reveals a tumorigenic role of adenylate cyclase in fumarate hydratase-deficient cancer cells.New insights into the biology of renal cell carcinoma Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL.8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition NCI's provocative questions on cancer: some answers to ignite discussion.Expression and purification of Src-family kinases for solution NMR studies.Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.Toward personalized cancer nanomedicine - past, present, and future.Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein.Cyclin D1 overexpression perturbs DNA replication and induces replication-associated DNA double-strand breaks in acquired radioresistant cells Towards a compendium of essential genes - From model organisms to synthetic lethality in cancer cells.Harnessing synthetic lethal interactions in anticancer drug discovery The VHL/HIF axis in clear cell renal carcinoma.Kinase requirements in human cells: I. Comparing kinase requirements across various cell types Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth Tyrosine phosphorylation: thirty years and counting.

P2860

Q24626537-5784F69C-75C0-42C4-B149-6CB0A6248C35 Q24629323-09602769-01C7-491A-9CAE-3B56E86E8D14 Q24630685-335FEDF8-E3A7-414A-99E3-F6A3BD756BDA Q26741450-63959370-0365-4375-914F-67203E3D4C37 Q26824642-1D6EE4C1-10E7-42A7-8C44-D790DB32128F Q28072166-679EC970-3935-4733-9A8B-433539DD53F2 Q29615757-2D14FE5C-D564-469A-B6E7-DF91F0CECBFE Q33558169-0413E426-2E99-49E8-A659-7DF76EC627FF Q33651791-6FF90F1A-E737-45FE-BAB4-5A808CDC9561 Q33662727-42183C5E-F367-47F3-8CC5-EA6204B0E52F Q33734672-0B95B8C3-0854-48C8-93B2-CF67B2B4095D Q33875574-3F798B7D-582E-43AD-87BE-9044D46E045C Q33923357-458D9587-E88E-4CA8-909F-8AC4732D4F66 Q33941657-CCAC9886-8978-40BE-BD91-835CC8A645FE Q34005003-42D8836E-4C54-44CC-9B86-ED060012DD06 Q34124493-3AF37126-A53D-493C-9FA0-35467F9D273A Q34455226-0A12DBA4-DEB9-4F93-8B17-1C294734BFF6 Q34636002-D7F3AFAE-B8C3-40EA-B2E8-A3A1BB9F6A0D Q34782184-16297DE3-55B9-47C3-97FD-F8DF538891B6 Q35102797-B32DAB95-299F-4C66-85BB-14AF910A88F9 Q35180400-F5CC5B52-4FA5-4504-96D6-A73EFC921C4D Q35589987-3505D61D-37B7-4DF0-9EAB-E4DCB2319EF2 Q35757283-525BE47F-A171-4298-8945-2E9B4A3474B1 Q35764401-E9AB2B57-1A9E-45E0-856D-04BBF641EA1D Q35835262-71217D17-6140-4570-B09B-4833BBD5261A Q36191526-C0652D16-C412-4014-BDF9-AE1FAE22ED1F Q36231927-0D788F5F-5C16-4E01-8010-FFE08FE7D4D5 Q36256943-9C916D9D-D2BC-462A-85D5-A72DCEDF981F Q36281483-952263E4-43B5-4437-A059-FC3D987F5D05 Q36472802-C0B9AD65-3337-42BC-A672-3BB1C5F75D05 Q36557866-200BFA4E-4AE3-42B0-BEA8-163F967549A0 Q36668449-4279A4CE-DA1D-4288-81CE-ED1204C95B12 Q36724277-5D16FAED-68B5-42B7-A2AC-94CA590513D2 Q36762503-50C8B0FF-4A0E-4B89-BDCF-3E5D56949D1E Q36839571-A4A4987C-DD5B-4D5F-98A1-B278DE16F4DE Q36872295-D9AB75CA-CA02-47BA-A973-EC5605BB0B97 Q36954852-4A889624-4EF2-457E-A272-74936D9DC00A Q36954863-90CCE9D9-688C-4637-B883-F460692F0FE8 Q37223809-3D4566D7-CFF5-4B24-AC77-8C66CDADE2EB Q37408903-DF2B52C5-6DF2-4260-9362-FD9D3BECCA1A

P2860

Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen.

http://www.wikidata.org/entity/Q36954859

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Kinase requirements in human c ...... pilot synthetic lethal screen.

@en

type

label

Kinase requirements in human c ...... pilot synthetic lethal screen.

@en

prefLabel

Kinase requirements in human c ...... pilot synthetic lethal screen.

@en

P1433

Q36954859-331C5BD0-E91C-4EF3-A473-EF6C548CED2B

P1476

Q36954859-03EE9167-32BE-48A7-AC29-98D74E571FD0

P2093

Q36954859-0B5B58CE-035E-4974-AD59-3859777613E1

Q36954859-3373E886-2513-4A6C-AA8D-467013389D5A

Q36954859-54DCF936-3804-456D-938C-7F738C9B7CCB

Q36954859-5A6635BB-3A34-41C6-AFCF-E1C790C12E0B

Q36954859-7742B5B4-2E56-47A9-A495-0039CFC391AB

Q36954859-8AFFB21F-16C8-4EFA-8C5A-F624EC7DD0E6

Q36954859-D24564F0-AE9C-49F8-A517-1A71678F701C

P2860

Q36954859-0281896B-6B7F-434F-8833-CA43B37AA191

Q36954859-0324168C-3748-4DB0-B82E-5CF49D72CD3B

Q36954859-0965A6D9-DED0-4DF4-AD00-AE9E40618045

Q36954859-0D0D610A-8796-4126-B420-9C1B9FD811CF

Q36954859-15E532F8-8EE4-4945-977B-C5CF66387364

Q36954859-1C4573A1-DA6D-400C-AAE2-9464755732CF

Q36954859-2C28F75A-0B75-4157-87DC-1F8D745578E4

Q36954859-3475F2D3-D62D-4B08-84F9-EEED8EC71BAF

Q36954859-456F9E23-548D-42ED-80D3-14FCA3A2BAC3

Q36954859-4C84BBAD-6373-4962-89D1-C79D8C2AA729

P304

Q36954859-8B45523A-B7A6-4ED3-ADA3-91EF30110E61

P31

Q36954859-A9EFA95C-48BB-468D-AF60-B6BE154878C5

P356

Q36954859-6EF14BE6-24BD-4ED9-9889-0C372DE49A61

P407

Q36954859-7DBF933E-B899-437B-91F4-7D93CF286DFA

P433

Q36954859-3CC367C9-1E94-43B5-BC1D-165252D57818

P478

Q36954859-493D982B-BC1E-4976-ABBF-7E9606125F32

P50

Q36954859-1C95F6A6-69F2-4D74-AD65-065BEF8EF3CB

P577

Q36954859-C360DED8-FE1C-48A9-936D-0121B1CD68F5

P5875

Q36954859-1DE59023-5798-47B2-9FFE-590803D52073

P698

Q36954859-399CFB06-1012-4B13-B785-2B25B6826A53

P932

Q36954859-F213DCB0-1D46-4139-AD1F-F6A8ABC28282

P356

PNAS.0806574105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Kinase requirements in human c ...... pilot synthetic lethal screen.

@en

P2093

Archana Bommi-Reddy

http://www.w3.org/2001/XMLSchema#string

Christoph Geisen

http://www.w3.org/2001/XMLSchema#string

Dorre A Grueneberg

http://www.w3.org/2001/XMLSchema#string

Ed Harlow

http://www.w3.org/2001/XMLSchema#string

Ingrid Almeciga

http://www.w3.org/2001/XMLSchema#string

Jacqueline Sawyer

http://www.w3.org/2001/XMLSchema#string

Wenliang Li

http://www.w3.org/2001/XMLSchema#string

P2860

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

Targeting HIF-1 for cancer therapy

Global mapping of the yeast genetic interaction network.

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

The concept of synthetic lethality in the context of anticancer therapy

Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis

TM4: a free, open-source system for microarray data management and analysis

P304

16484-16489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0806574105

http://www.w3.org/2001/XMLSchema#string

P407

P433

43

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

William G. Kaelin

P577

2008-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23411128

http://www.w3.org/2001/XMLSchema#string

P698

18948595

http://www.w3.org/2001/XMLSchema#string

P932

2575446

http://www.w3.org/2001/XMLSchema#string